{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:38:23Z","timestamp":1794580703220,"version":"4.9.1"},"reference-count":27,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The National Heart, Lung, and Blood Institute\u2013funded National MDS Natural History Study (NCT02775383) is a prospective cohort study enrolling patients with cytopenia with suspected myelodysplastic syndromes (MDS) to evaluate factors associated with disease. Here, we sequenced 53 genes in bone marrow samples harvested from 1298 patients diagnosed with myeloid malignancy, including MDS and non-MDS myeloid malignancy or alternative marrow conditions with cytopenia based on concordance between independent histopathologic reviews (local, centralized, and tertiary to adjudicate disagreements when needed). We developed a novel 2-stage diagnostic classifier based on mutational profiles in 18 of 53 sequenced genes that were sufficient to best predict a diagnosis of myeloid malignancy and among those with a predicted myeloid malignancy, predict whether they had MDS. The classifier achieved a positive predictive value (PPV) of 0.84 and negative predictive value (NPV) of 0.8 with an area under the receiver operating characteristic curve (AUROC) of 0.85 when classifying patients as having myeloid vs no myeloid malignancy based on variant allele frequencies (VAFs) in 17 genes and a PPV of 0.71 and NPV of 0.64 with an AUROC of 0.73 when classifying patients as having MDS vs non-MDS malignancy based on VAFs in 10 genes. We next assessed how this approach could complement histopathology to improve diagnostic accuracy. For 99 of 139 (71%) patients (PPV of 0.83 and NPV of 0.65) with local and centralized histopathologic disagreement in myeloid vs no myeloid malignancy, the classifier-predicted diagnosis agreed with the tertiary pathology review (considered the internal gold standard).<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008578","type":"journal-article","created":{"date-parts":[[2023,3,22]],"date-time":"2023-03-22T16:04:20Z","timestamp":1679501060000},"page":"3749-3759","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":11,"title":["Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditions"],"prefix":"10.1182","volume":"7","author":[{"given":"Amy E.","family":"DeZern","sequence":"first","affiliation":[{"name":"1Sidney Kimmel Cancer Center, Baltimore, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9968-4080","authenticated-orcid":false,"given":"Johannes B.","family":"Goll","sequence":"additional","affiliation":[{"name":"2The Emmes Company, LLC, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9822-806X","authenticated-orcid":false,"given":"R. Coleman","family":"Lindsley","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Bejar","sequence":"additional","affiliation":[{"name":"4Moores Cancer Center, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffanie H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"2The Emmes Company, LLC, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donnie","family":"Hebert","sequence":"additional","affiliation":[{"name":"2The Emmes Company, LLC, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Deeg","sequence":"additional","affiliation":[{"name":"5Fred Hutchison Cancer Research Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"6H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gore","sequence":"additional","affiliation":[{"name":"7National Cancer Institute, National Institutes of Health, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tareq","family":"Al Baghdadi","sequence":"additional","affiliation":[{"name":"8Michigan Cancer Research Consortium, Ypsilanti, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslaw","family":"Maciejewski","sequence":"additional","affiliation":[{"name":"9Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Liu","sequence":"additional","affiliation":[{"name":"10Illinois CancerCare, Peoria, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[{"name":"6H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1876-5269","authenticated-orcid":false,"given":"Rami","family":"Komrojki","sequence":"additional","affiliation":[{"name":"6H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[{"name":"11Center for International Blood and Marrow Transplant Research, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Abel","sequence":"additional","affiliation":[{"name":"3Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4723-6307","authenticated-orcid":false,"given":"Steven H.","family":"Kroft","sequence":"additional","affiliation":[{"name":"12Froedtert Hospital, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Harrington","sequence":"additional","affiliation":[{"name":"13Kern Institute, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5653-3418","authenticated-orcid":false,"given":"Tyler","family":"Grimes","sequence":"additional","affiliation":[{"name":"2The Emmes Company, LLC, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0711-2932","authenticated-orcid":false,"given":"Harrison","family":"Reed","sequence":"additional","affiliation":[{"name":"2The Emmes Company, LLC, Rockville, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Fulton","sequence":"additional","affiliation":[{"name":"14McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy L.","family":"DiFronzo","sequence":"additional","affiliation":[{"name":"15National Institutes of Health, National Heart, Lung, and Blood Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7744-8490","authenticated-orcid":false,"given":"Nancy","family":"Gillis","sequence":"additional","affiliation":[{"name":"6H. Lee Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[{"name":"16Sylvester Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7753-1091","authenticated-orcid":false,"given":"Matthew J.","family":"Walter","sequence":"additional","affiliation":[{"name":"17Department of Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,7,18]]},"reference":[{"issue":"7","key":"2023072117502131600_bib1","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1634\/theoncologist.2014-0056","article-title":"The challenging world of cytopenias: distinguishing myelodysplastic syndromes from other disorders of marrow failure","volume":"19","author":"DeZern","year":"2014","journal-title":"Oncologist"},{"issue":"11","key":"2023072117502131600_bib2","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.2021011323","article-title":"Relationship between clone metrics and clinical outcome in clonal cytopenia","volume":"138","author":"Galli","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023072117502131600_bib3","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"issue":"13","key":"2023072117502131600_bib4","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1080\/10428194.2019.1616186","article-title":"The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes","volume":"60","author":"Sekeres","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2023072117502131600_bib5","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1182\/blood-2011-03-342642","article-title":"Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers","volume":"118","author":"Naqvi","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2023072117502131600_bib6","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-012-1565-4","article-title":"Inter-observer variance with the diagnosis of myelodysplastic syndromes (MDS) following the 2008 WHO classification","volume":"92","author":"Font","year":"2013","journal-title":"Ann Hematol"},{"issue":"4","key":"2023072117502131600_bib7","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/s41375-020-0997-4","article-title":"Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)","volume":"35","author":"Yun","year":"2021","journal-title":"Leukemia"},{"issue":"21","key":"2023072117502131600_bib8","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2023072117502131600_bib9","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2023072117502131600_bib10","doi-asserted-by":"crossref","first-page":"EVIDoa2200008","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evidence"},{"issue":"11","key":"2023072117502131600_bib11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.clml.2016.08.005","article-title":"Changes in the updated 2016: WHO classification of the myelodysplastic syndromes and related myeloid neoplasms","volume":"16","author":"Bennett","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2023072117502131600_bib12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/leu.2016.282","article-title":"Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy","volume":"31","author":"Uy","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2023072117502131600_bib13","doi-asserted-by":"crossref","first-page":"e98962","DOI":"10.1172\/jci.insight.98962","article-title":"Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant","volume":"3","author":"Jacoby","year":"2018","journal-title":"JCI Insight"},{"issue":"3","key":"2023072117502131600_bib14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jmoldx.2021.10.013","article-title":"Failure to detect mutations in U2AF1 due to changes in the GRCh38 reference sequence","volume":"24","author":"Miller","year":"2022","journal-title":"J\u00a0Mol Diagn"},{"issue":"3","key":"2023072117502131600_bib15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"issue":"1","key":"2023072117502131600_bib16","first-page":"1","article-title":"Regularization paths for generalized linear models via coordinate descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J\u00a0Stat Softw"},{"issue":"1","key":"2023072117502131600_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2023072117502131600_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3324\/haematol.2012.071449","article-title":"Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes","volume":"98","author":"Senent","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"2023072117502131600_bib19","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3324\/haematol.2011.056879","article-title":"Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors","volume":"97","author":"Parmentier","year":"2012","journal-title":"Haematologica"},{"issue":"7","key":"2023072117502131600_bib20","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"2023072117502131600_bib21","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"43","key":"2023072117502131600_bib22","doi-asserted-by":"crossref","first-page":"73483","DOI":"10.18632\/oncotarget.19008","article-title":"Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions","volume":"8","author":"Valent","year":"2017","journal-title":"Oncotarget"},{"issue":"25","key":"2023072117502131600_bib23","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023072117502131600_bib24","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(19)30211-X","article-title":"Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states","volume":"7","author":"Gondek","year":"2020","journal-title":"Lancet Haematol"},{"issue":"21","key":"2023072117502131600_bib25","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1182\/blood-2015-08-663237","article-title":"Targeted sequencing identifies patients with preclinical MDS at high risk of disease progression","volume":"126","author":"Cargo","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2023072117502131600_bib26","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1038\/leu.2016.247","article-title":"Targeted sequencing informs the evaluation of normal karyotype cytopenic patients for low-grade myelodysplastic syndrome","volume":"30","author":"Duncavage","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"2023072117502131600_bib27","doi-asserted-by":"crossref","first-page":"e602","DOI":"10.1038\/bcj.2017.82","article-title":"Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes","volume":"7","author":"Nazha","year":"2017","journal-title":"Blood Cancer J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3749\/2065344\/blooda_adv-2022-008578-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/14\/3749\/2065344\/blooda_adv-2022-008578-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T18:35:30Z","timestamp":1689964530000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/14\/3749\/495027\/Utility-of-targeted-gene-sequencing-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,18]]},"references-count":27,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,7,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008578","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,18]]}}}